@synsci/cli-darwin-x64 1.1.97 → 1.1.99

package/bin/skills/clinical-reports/references/clinical_trial_reporting.md

@@ -1,693 +0,0 @@
-# Clinical Trial Reporting Standards
-
-## ICH-E3: Structure and Content of Clinical Study Reports
-
-The International Council for Harmonisation (ICH) E3 guideline defines the structure and content of clinical study reports (CSRs) for regulatory submission.
-
-### CSR Overview
-
-**Purpose:**
-- Provide comprehensive description of study design, conduct, and results
-- Support regulatory decision-making
-- Document evidence of safety and efficacy
-
-**Audience:**
-- Regulatory authorities (FDA, EMA, PMDA, etc.)
-- Medical reviewers
-- Statistical reviewers
-- Clinical pharmacology reviewers
-
-**Length:** Typically 50-300 pages (main text), with extensive appendices
-
-### Main Sections of ICH-E3 CSR
-
-#### Section 1: Title Page
-
-**Required elements:**
-- Full study title
-- Protocol number and version
-- Sponsor name and address
-- Compound/drug name and code
-- Study phase
-- Indication
-- Report date and version number
-- Report authors
-- Confidentiality statement
-
-#### Section 2: Synopsis
-
-**Length:** 5-15 pages
-
-**Content:**
-- Brief summary of entire CSR
-- Must be understandable as standalone document
-- Cover all major sections
-
-**Standard synopsis elements:**
-1. Study identifier and title
-2. Study objectives
-3. Methodology:
-   - Study design
-   - Number and description of patients
-   - Diagnosis and main criteria for inclusion
-   - Study treatments
-   - Duration of treatment
-   - Criteria for evaluation
-   - Statistical methods
-4. Results:
-   - Number of patients enrolled, completed, discontinued
-   - Efficacy results
-   - Safety results
-5. Conclusions
-
-#### Section 3: Ethics
-
-**3.1 Independent Ethics Committee/Institutional Review Board**
-- Names and locations of all IRBs
-- Dates of initial approval
-- Dates of protocol amendment approvals
-- Documentation of continuing review
-
-**3.2 Ethical Conduct of Study**
-- Statement of compliance with GCP and Declaration of Helsinki
-- Protocol adherence
-- Informed consent process
-
-**3.3 Patient Information and Consent**
-- Description of informed consent procedures
-- Consent form versions used
-- Process for re-consent if applicable
-
-#### Section 4: Investigators and Study Administrative Structure
-
-**4.1 Investigators**
-- List of principal investigators by site
-- Site addresses and enrollment
-- Coordinating investigator (if applicable)
-
-**4.2 Administrative Structure**
-- Sponsor personnel and roles
-- CRO involvement (if applicable)
-- Monitoring procedures
-- Data management organization
-- Statistical analysis organization
-
-**4.3 Study Monitoring and Quality Assurance**
-- Monitoring procedures and frequency
-- Source document verification
-- Quality control procedures
-- Audits performed
-
-#### Section 5: Introduction
-
-**5.1 Background**
-- Disease or condition being studied
-- Current treatment landscape
-- Unmet medical need
-
-**5.2 Investigational Product**
-- Pharmacology and mechanism of action
-- Nonclinical findings
-- Prior clinical experience
-- Known safety profile
-
-**5.3 Non-Investigational Therapy**
-- Comparator drugs or placebo
-- Concomitant medications allowed/prohibited
-
-#### Section 6: Study Objectives
-
-**6.1 Primary Objective**
-- Main research question
-- Clearly stated and specific
-- Example: "To evaluate the efficacy of Drug X compared to placebo in reducing HbA1c in patients with type 2 diabetes mellitus over 24 weeks of treatment"
-
-**6.2 Secondary Objectives**
-- Additional research questions
-- Supportive efficacy endpoints
-- Safety objectives
-- Exploratory objectives
-
-**6.3 Endpoints**
-- Primary endpoint definition and measurement
-- Secondary endpoints
-- Safety endpoints
-- Pharmacokinetic endpoints (if applicable)
-- Biomarker endpoints (if applicable)
-
-#### Section 7: Investigational Plan
-
-**7.1 Overall Study Design and Plan**
-- Study design type (parallel, crossover, factorial, etc.)
-- Randomization and blinding
-- Study phases or periods
-- Duration of treatment and follow-up
-- Dosing regimen
-- Study flow diagram (patient flowchart)
-
-**7.2 Sample Size**
-- Target enrollment
-- Sample size justification
-- Power calculation assumptions:
-  - Expected effect size
-  - Variability estimates
-  - Type I error (alpha)
-  - Power (1 - beta)
-  - Drop-out rate assumptions
-
-**7.3 Statistical Methods**
-- Analysis populations (ITT, PP, safety)
-- Handling of missing data
-- Interim analyses (if planned)
-- Multiplicity adjustments
-- Subgroup analyses
-- Sensitivity analyses
-
-**7.4 Changes to Protocol**
-- Protocol amendments and rationale
-- Impact on study conduct and analysis
-
-#### Section 8: Study Patients
-
-**8.1 Inclusion and Exclusion Criteria**
-- Key inclusion criteria
-- Key exclusion criteria
-- Rationale for criteria
-
-**8.2 Demographic and Baseline Characteristics**
-- Age, sex, race/ethnicity
-- Disease severity or stage
-- Prior therapies
-- Baseline values of key endpoints
-- Comparability across treatment groups
-
-**8.3 Patient Disposition**
-- Number screened
-- Number randomized
-- Number completing study
-- Number withdrawn (by reason)
-- Number lost to follow-up
-- CONSORT flow diagram
-
-**8.4 Protocol Deviations**
-- Major protocol deviations
-- Minor protocol deviations
-- Impact on efficacy and safety analyses
-- Corrective actions taken
-
-**8.5 Demographic and Other Baseline Characteristics**
-- Detailed demographic tables
-- Baseline disease characteristics
-- Stratification factors
-- Medical history
-- Prior/concomitant medications
-
-#### Section 9: Efficacy Evaluation
-
-**9.1 Data Sets Analyzed**
-- Intent-to-treat (ITT) population
-- Per-protocol (PP) population
-- Modified ITT
-- Other analysis sets
-- Justification for population definitions
-
-**9.2 Demographic and Baseline Characteristics**
-- Demographics by analysis population
-- Baseline comparability
-
-**9.3 Measurements of Treatment Compliance**
-- Drug accountability
-- Pill counts or diary compliance
-- Plasma drug levels (if measured)
-- Percent of planned dose received
-
-**9.4 Efficacy Results**
-
-**9.4.1 Primary Endpoint**
-- Results for primary endpoint
-- Statistical analysis
-- Effect size and confidence intervals
-- P-values
-- Subgroup analyses
-
-**9.4.2 Secondary Endpoints**
-- Results for each secondary endpoint
-- Statistical analyses
-- Hierarchy of testing (if applicable)
-
-**9.4.3 Other Efficacy Endpoints**
-- Exploratory endpoints
-- Post-hoc analyses
-- Responder analyses
-
-**9.5 Dropouts and Missing Data**
-- Patterns of missing data
-- Reasons for dropout
-- Sensitivity analyses for missing data
-
-#### Section 10: Safety Evaluation
-
-**10.1 Extent of Exposure**
-- Duration of exposure
-- Dose intensity
-- Dose delays or reductions
-- Treatment discontinuations due to adverse events
-
-**10.2 Adverse Events**
-
-**10.2.1 Overview of Adverse Events**
-- Summary tables (any AE, treatment-related, serious, leading to discontinuation)
-- Percentage of patients with AEs
-- Comparison across treatment groups
-
-**10.2.2 Common Adverse Events**
-- AEs occurring in ≥5% or ≥10% of patients
-- Sorted by frequency
-- Preferred terms and system organ class (MedDRA)
-
-**10.2.3 Serious Adverse Events**
-- Definition of SAE
-- Summary table of SAEs
-- Individual narratives for each SAE
-- Causality assessment
-- Outcome
-
-**10.2.4 Adverse Events Leading to Discontinuation**
-- AEs leading to study drug discontinuation
-- Frequency and type
-- Relationship to study drug
-
-**10.2.5 Deaths**
-- All deaths during study and follow-up
-- Detailed narratives for each death
-- Relationship to study drug
-- Autopsy findings (if available)
-
-**10.3 Clinical Laboratory Evaluations**
-- Laboratory abnormalities
-- Shift tables (normal to abnormal, abnormal to normal)
-- Mean changes from baseline
-- Laboratory values meeting protocol-defined criteria
-- Hepatotoxicity monitoring (if applicable)
-
-**10.4 Vital Signs and Physical Findings**
-- Vital signs (BP, HR, temperature, respiratory rate)
-- Mean changes from baseline
-- Clinically significant changes
-- Physical examination findings
-
-**10.5 ECG Evaluation**
-- QTc interval changes
-- Other ECG abnormalities
-- Clinically significant ECG findings
-
-**10.6 Special Safety Evaluations**
-- Immunogenicity (for biologics)
-- Pregnancy outcomes (if applicable)
-- Abuse potential (if applicable)
-- Withdrawal or rebound effects
-- Dependency potential
-
-#### Section 11: Discussion and Overall Conclusions
-
-**11.1 Efficacy Discussion**
-- Interpretation of efficacy results
-- Clinical significance of findings
-- Consistency with prior studies
-- Limitations
-
-**11.2 Safety Discussion**
-- Safety profile overview
-- Notable safety findings
-- Comparison to known safety profile
-- Risk-benefit assessment
-
-**11.3 Benefit-Risk Assessment**
-- Overall benefit-risk conclusion
-- Subpopulations with favorable/unfavorable benefit-risk
-- Implications for dosing or patient selection
-
-**11.4 Clinical Implications**
-- Place in therapy
-- Target patient population
-- Comparison to existing therapies
-
-#### Section 12: Tables, Figures, and Graphs
-
-Comprehensive set of tables and figures for efficacy and safety data.
-
-**Common tables:**
-- Demographic and baseline characteristics
-- Patient disposition
-- Extent of exposure
-- Efficacy results (primary and secondary endpoints)
-- Adverse event summary
-- Common adverse events
-- Serious adverse events
-- Deaths
-- Laboratory abnormalities
-- Vital signs
-
-**Common figures:**
-- Study design schematic
-- Patient disposition flowchart (CONSORT)
-- Kaplan-Meier curves (survival, time to event)
-- Forest plots (subgroup analyses)
-- Mean change over time plots
-
-#### Section 13: References
-
-- Publications cited in CSR
-- Relevant literature
-- Regulatory guidelines
-- Prior study reports
-
-#### Section 14: Appendices
-
-**Required appendices:**
-- Study protocol and amendments
-- Sample case report forms
-- Investigator list with IRB information
-- Patient information and informed consent forms
-- List of patients receiving study drug
-- Randomization scheme
-- Audit certificates (if applicable)
-- Documentation of statistical methods
-- Publications based on study
-
-**Optional appendices:**
-- Individual patient data listings
-- SAE narratives
-- Laboratory normals and conversion factors
-- Investigator signatures
-
-### Statistical Analysis Plan (SAP)
-
-**SAP Components:**
-- Analysis populations
-- Handling of missing data
-- Statistical tests to be used
-- Adjustment for multiplicity
-- Interim analysis plan
-- Subgroup analyses
-- Sensitivity analyses
-- Safety analyses
-
-**SAP Timing:**
-- Finalized before database lock
-- Amendments documented with rationale
-
-## CONSORT (Consolidated Standards of Reporting Trials)
-
-CONSORT guidelines promote transparent and complete reporting of randomized controlled trials.
-
-### CONSORT 2010 Checklist
-
-#### Title and Abstract
-- **1a. Title**: Identification as randomized trial in title
-- **1b. Abstract**: Structured summary covering trial design, methods, results, conclusions
-
-#### Introduction
-- **2a. Background**: Scientific background and explanation of rationale
-- **2b. Objectives**: Specific objectives or hypotheses
-
-#### Methods - Participants
-- **3a. Eligibility**: Eligibility criteria for participants
-- **3b. Settings**: Settings and locations of data collection
-
-#### Methods - Interventions
-- **4a. Interventions**: Details of interventions for each group
-- **4b. Details**: Sufficient details to allow replication
-
-#### Methods - Outcomes
-- **5. Outcomes**: Clearly defined primary and secondary outcome measures
-- **6a. Sample size**: How sample size was determined
-- **6b. Interim analyses**: When applicable, explanation of interim analyses
-
-#### Methods - Randomization
-- **7a. Sequence generation**: Method of random sequence generation
-- **7b. Allocation concealment**: Mechanism of allocation concealment
-- **8a. Implementation**: Who generated allocation, enrolled, and assigned participants
-- **8b. Blinding**: Whether participants, care providers, outcome assessors were blinded
-
-#### Methods - Statistical
-- **9. Statistical methods**: Methods for primary and secondary outcomes
-- **10. Additional analyses**: Subgroup or adjusted analyses
-
-#### Results - Participant Flow
-- **11a. Enrollment**: Numbers screened, randomized, allocated
-- **11b. Losses and exclusions**: For each group, losses and exclusions after randomization
-- **12. Recruitment**: Dates defining recruitment and follow-up periods
-- **13a. Baseline**: Baseline demographic and clinical characteristics
-- **13b. Baseline comparability**: Numbers analyzed in each group
-
-#### Results - Outcomes and Estimation
-- **14a. Outcomes**: For primary and secondary outcomes, results for each group
-- **14b. Binary outcomes**: For binary outcomes, effect sizes and confidence intervals
-- **15. Ancillary analyses**: Results of other analyses performed
-
-#### Results - Harms
-- **16. Harms**: All important harms or unintended effects in each group
-
-#### Discussion
-- **17a. Limitations**: Trial limitations, addressing biases, imprecision
-- **17b. Generalizability**: Generalizability (external validity) of trial findings
-- **18. Interpretation**: Interpretation consistent with results, balancing benefits and harms
-- **19. Registration**: Registration number and name of trial registry
-- **20. Protocol**: Where full trial protocol can be accessed
-- **21. Funding**: Sources of funding, role of funders
-
-### CONSORT Flow Diagram
-
-Standard format showing patient flow through trial:
-```
-Assessed for eligibility (n=)
-    ↓
-Randomized (n=)
-    ├─ Allocated to intervention (n=)
-    │   ├─ Received intervention (n=)
-    │   └─ Did not receive intervention (n=)
-    │       Give reasons
-    ├─ Allocated to control (n=)
-    │   ├─ Received control (n=)
-    │   └─ Did not receive control (n=)
-    │       Give reasons
-    ↓
-Lost to follow-up (n=)
-    Give reasons
-Discontinued intervention (n=)
-    Give reasons
-    ↓
-Analyzed (n=)
-Excluded from analysis (n=)
-    Give reasons
-```
-
-## Serious Adverse Event (SAE) Reporting
-
-### Definition of Serious Adverse Event
-
-An adverse event or suspected adverse reaction is considered serious if it:
-- Results in death
-- Is life-threatening
-- Requires inpatient hospitalization or prolongation of existing hospitalization
-- Results in persistent or significant disability/incapacity
-- Is a congenital anomaly/birth defect
-- Requires intervention to prevent permanent impairment or damage (device-related)
-- Other medically important events (based on medical judgment)
-
-### SAE Report Components
-
-**1. Administrative Information**
-- Report type (initial, follow-up, final)
-- Report number
-- Date of report
-- Reporter information
-- Sponsor information
-- Study identifier (protocol number, NCT number)
-
-**2. Patient Information (De-identified)**
-- Subject ID or randomization number
-- Initials (if permitted)
-- Age or date of birth (year only)
-- Sex
-- Race/ethnicity
-- Weight
-- Height
-
-**3. Study Information**
-- Study phase (I, II, III, IV)
-- Study design (randomized, open-label, etc.)
-- Treatment arm or randomization
-- Date of first study drug
-- Date of last study drug
-
-**4. Event Information**
-- Reported term (verbatim)
-- MedDRA preferred term
-- System organ class
-- Date of onset
-- Time of onset (if relevant)
-- Date of resolution (or ongoing)
-- Duration
-
-**5. Seriousness Criteria**
-- Death: Yes/No
-- Life-threatening: Yes/No
-- Hospitalization required: Yes/No
-- Hospitalization prolonged: Yes/No
-- Disability/incapacity: Yes/No
-- Congenital anomaly: Yes/No
-- Medically significant: Yes/No
-
-**6. Severity**
-- Mild: Noticeable but does not interfere with daily activities
-- Moderate: Interferes with daily activities but manageable
-- Severe: Prevents usual daily activities, requires intervention
-
-Note: Severity ≠ Seriousness
-
-**7. Outcome**
-- Recovered/resolved
-- Recovering/resolving
-- Not recovered/not resolved
-- Recovered/resolved with sequelae
-- Fatal
-- Unknown
-
-**8. Causality Assessment**
-- Relationship to study drug:
-  - Not related
-  - Unlikely related
-  - Possibly related
-  - Probably related
-  - Definitely related
-- Relationship to study procedures
-- Relationship to underlying disease
-- Relationship to concomitant medications
-- Reasoning for determination
-
-**9. Expectedness**
-- Expected (per Investigator's Brochure or protocol)
-- Unexpected (not in IB or more severe than documented)
-
-**10. Action Taken with Study Drug**
-- No change
-- Dose reduced
-- Dose increased
-- Drug interrupted (temporarily held)
-- Drug discontinued
-- Not applicable (event occurred after discontinuation)
-
-**11. Treatments/Interventions for Event**
-- Medications administered
-- Procedures performed
-- Hospitalization details
-- ICU admission
-- Surgical intervention
-
-**12. Event Narrative**
-- Detailed description of event
-- Timeline of events
-- Clinical course
-- Relevant medical history
-- Concomitant medications
-- Diagnostic test results
-- Treatment and response
-- Outcome and current status
-
-**Example narrative:**
-```
-A 58-year-old male (Subject ID: 12345) enrolled in Study XYZ-301, a Phase 3
-randomized trial of Drug X vs. placebo for heart failure. On Day 42 of treatment
-(15-Feb-2024), the patient presented to the emergency department with sudden onset
-severe chest pain, diaphoresis, and dyspnea. ECG showed ST-segment elevation in
-leads V2-V4. Troponin I was elevated at 12.5 ng/mL (normal <0.04). The patient was
-diagnosed with acute ST-elevation myocardial infarction and underwent emergent
-cardiac catheterization revealing 95% occlusion of the left anterior descending
-artery. Percutaneous coronary intervention with drug-eluting stent placement was
-performed successfully. The patient was admitted to the cardiac intensive care unit.
-Study drug was permanently discontinued on Day 42. The patient recovered and was
-discharged on Day 47 (20-Feb-2024) in stable condition. This event was assessed as
-unlikely related to study drug by the investigator, as the patient had significant
-underlying coronary artery disease risk factors including diabetes, hypertension,
-and smoking history.
-```
-
-### Regulatory Reporting Timelines
-
-**FDA IND Safety Reporting (21 CFR 312.32):**
-- **Fatal or life-threatening unexpected SAEs**: 7 calendar days for preliminary report, 15 days for complete report
-- **Other serious unexpected events**: 15 calendar days
-- **Annual safety reports**: Within 60 days of anniversary of IND
-
-**EMA Expedited Reporting:**
-- **Fatal or life-threatening unexpected events**: 7 days initial, 8 additional days for complete report
-- **Other unexpected serious events**: 15 days
-
-**IRB Reporting:**
-- Per institutional policy
-- Typically 5-10 days for serious unexpected events
-- Some institutions require reporting within 24-48 hours
-
-### MedDRA Coding
-
-**MedDRA (Medical Dictionary for Regulatory Activities):**
-- Standardized medical terminology for regulatory communication
-- Hierarchical structure:
-  - SOC (System Organ Class) - highest level
-  - HLGT (High Level Group Term)
-  - HLT (High Level Term)
-  - PT (Preferred Term) - used for coding AEs
-  - LLT (Lowest Level Term) - verbatim terms
-
-**Example:**
-- Verbatim term: "bad headache"
-- LLT: Headache
-- PT: Headache
-- HLT: Headaches NEC
-- HLGT: Neurological disorders NEC
-- SOC: Nervous system disorders
-
-### Causality Assessment Methods
-
-**WHO-UMC Causality Categories:**
-- **Certain**: Event cannot be explained by other factors
-- **Probable/Likely**: Event more likely related to drug than other factors
-- **Possible**: Event could be related to drug, but other factors cannot be ruled out
-- **Unlikely**: Event likely explained by other factors
-- **Conditional/Unclassified**: More data needed
-- **Unassessable/Unclassifiable**: Information insufficient
-
-**Naranjo Algorithm (for ADRs):**
-Scoring system based on 10 questions:
-- Score ≥9: Definite
-- Score 5-8: Probable
-- Score 1-4: Possible
-- Score ≤0: Doubtful
-
-## Data Safety Monitoring Board (DSMB)
-
-**Purpose:**
-- Independent review of safety data
-- Monitoring benefit-risk
-- Recommendations on study continuation
-
-**DSMB Charter Elements:**
-- Membership and qualifications
-- Roles and responsibilities
-- Meeting frequency
-- Data reviewed
-- Decision-making criteria
-- Communication procedures
-- Confidentiality
-
-**DSMB Reports:**
-- Open reports (all parties can see)
-- Closed reports (DSMB and sponsor only)
-- Recommendations: Continue, modify, or terminate study
-
----
-
-This reference provides comprehensive guidance for clinical trial reporting following ICH-E3 and CONSORT guidelines, as well as SAE reporting requirements. Use these standards when preparing regulatory submissions and trial publications.
-